SCIENCE@home

Screening and diagnosis of pulmonary hypertension associated with chronic lung disease (PH‐CLD): A consensus statement from the pulmonary vascular research institute's innovative drug development initiative—group 3 pulmonary hypertension

P. Vitulo,L. Piccari,S. J. Wort,O. Shlobin,G. Kovacs,C. Vizza,P. Hassoun,H. Olschewski,R. E. Girgis,S. Nikkho,S. Nathan,Steven H. Abman,B. Allwood,Katerina Antoniou,Irina Petrache,Mitchell Psotka,Prakash Sista,Bayer Boehringer Chiesi Gsk Iqvia Janssen Menarini Msd Astra Zeneca,Ludwig Novartis,Boltzmann

Published 2024 in Pulmonary Circulation

ABSTRACT

Abstract Pulmonary hypertension (PH) is a frequent complication of chronic lung disease (CLD). However, PH is difficult to diagnose early since accompanying symptoms overlap and are similar to those of the underlying CLD. In most cases the PH is mild to moderate and therefore physical signs may be absent or subtle. This consensus paper provides insight into the clues that might suggest the presence of occult PH in patients with CLD. An overview of current diagnostic tools and emerging diagnostic technologies is provided as well as guidance for the work‐up and diagnosis of PH in patients with CLD.

PUBLICATION RECORD

CITATION MAP

EXTRACTION MAP

CLAIMS

  • No claims are published for this paper.

CONCEPTS

  • No concepts are published for this paper.

REFERENCES

Showing 1-96 of 96 references · Page 1 of 1

CITED BY